Compares an SGLT2 inhibitor with other diabetes pills in atrial fibrillation
Compares an SGLT2 inhibitor with other diabetes pills in adults with atrial fibrillation and diabetes.
Key facts
- Who runs it
- Ewha Womans University Mokdong Hospital
- Where
- Yangcheon, South KoreaSee the site
- Trial code
- Registry title
- The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
- Status
- Enrolling by invitation
- People taking part
- 716 people, planned
- Started
- 5 Oct 2021
- Expected to end
- Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- SGLT2 inhibitor
- Record updated
- 23 January 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 to 80 with type 2 diabetes who had atrial fibrillation in the past year and take only oral diabetes medicines.
- Age
- 20 to 80 years
- Sex
- All sexes can join.
- Disease stage
- At least one atrial fibrillation episode recorded on an ECG in the past year. Type 2 diabetes with HbA1c above 6.5% (48 mmol/mol). Normal ECG measurements while in normal heart rhythm.
- Earlier treatment
- Only oral diabetes medicines are used. Previous treatment with any SGLT2 inhibitor or with AF ablation is not allowed. Treatment with insulin is not allowed.
- Biomarker or test result
- HbA1c above 6.5% (48 mmol/mol) at diagnosis (type 2 diabetes).
Main reasons for not taking part
- Illness that limits life expectancy to under 1 year
- Pregnant or breastfeeding women
- Type 2 diabetes treated with recombinant insulin, or type 1 diabetes, MODY or secondary diabetes
- Kidney problems (eGFR under 30 ml/min/1.73 m²)
- Heart attack, stroke or other acute heart event less than 8 weeks ago, or severe valve disease or a prosthetic valve
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- At least one episode of atrial fibrillation* that is documented during the prior year by any kind of ECG recording
- Diabetes mellitus type II was diagnosed. (HBA1c >6.5%) and are using oral hypoglycemic agents only
- At least 20 years old and not older than 80 years old
- Normal ECG parameters when measured in sinus rhythm (QRS width ≤120 ms, QTc interval <440 ms, and PQ interval ≤210 ms in a 12 lead ECG)
- Able and willing to give informed consent
Who cannot take part
- Drug abuser
- Previous treatment with any SGLT2 inhibitor
- Previous treatment with AF ablation
- Acute cardiovascular event [e.g., stroke, acute coronary syndrome (ACS), revascularization, decompensated HF, sustained ventricular tachycardia, return of spontaneous circulation (ROSC)] <8 weeks prior to baseline study
- Treatment with chronic oral steroid (>30 consecutive days) at a dose equivalent to oral prednisolone ≥10mg/d, within the past 1 month
- Any disease that limits life expectancy under 1 year
- Chronic cystitis and/or recurrent genitourinary tract infections (3 or more in the last year)
- Severe valvular disease or have prosthetic valve
- History of any malignancy within 5 years
- Patients incapable of completing the trial due to any severe medical condition by clinical decision
- HbA1c ≥12% or HbA1c <6.5% at diagnosis
- Renal dysfunction (eGFR-CKD-EPI <30ml/min/1.73m\^2)
- Under 20 years old or over 80 years old
- Subject for another clinical trial within the past 2 months
- Pregnant women
- Lactating women
- Type 2 DM treated by recombinant insulin
- Diagnosis of Type 1 DM, MODY, or secondary DM
- Unexplained hematuria at baseline study
- Systolic BP >180mmHg or diastolic BP >100mmHg at baseline study
- Systolic BP <95mmHg at baseline study
- Clinically profound hepatic dysfunction
- Clinically uncontrolled thyroid dysfunction
- Patients with poor compliance (defined as 80 - 120%), except for reasonable situations judged by physician
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Where in South Korea
- Ewha womans university mokdong hospitalYangcheon, South KoreaEnrolling by invitation
About the trial
What the trial wants to find out
This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus. We are to compare efficacy and safety between these two groups.
The 2 groups in the trial
- SGLT-2 inhibitor administration group
The group who administrated SGLT-2 inhibitor for hypoglycemic medication
Treatment: SGLT2 inhibitor
- control
The group who are not administrated SGLT-2 inhibitor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
- Plain-language title
- Compares an SGLT2 inhibitor with other diabetes pills in atrial fibrillationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05029115, who can take part
- Publications
- Record updated
- 23 January 2023